PACS Group PACS
United StatesHealthcare · Medical Care FacilitiesUSD
59.00 USD (+36.6%)
6 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
PACS Group, Inc. operates healthcare facilities in the United States, providing skilled nursing and post-acute care services, with revenue based on government and private reimbursements.
Key points
from its scores- ✓Good share-price trend9.8
- ✓Favourable backdrop8.7
- ✓Strong growth7.9
- ✕Little or no dividend1.5
- ✕Fragile balance sheet2.2
AI analysis
bottom line, main risk, context and newsGrowth and quality are attractive, but high debt and tight margins warrant caution.
PACS Group shows solid growth (revenue +9.1%, earnings +51.6%) and high profitability (ROE 27.92%), but its high leverage (Net Debt/EBITDA 6.77) and low operating margin (7.66%) are weaknesses that drag on its financial health.
High leverage (Net Debt/EBITDA 6.77) and dependence on government reimbursements (Medicare/Medicaid) are the biggest risks for PACS Group.
Context and risks
PACS Group operates in the healthcare facilities sector in the U.S., a sector with active regulatory oversight (Medicare/Medicaid reimbursements, licensing and compliance requirements). Although the country has strong institutions, exposure to changes in reimbursement policies and healthcare regulation is a material risk to its business model.
Is PACS Group stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 20% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 25.3 | 26.7 | −6% |
| EV / EBITDA | 21.1 | 14.5 | +46% |
| Price / book | 6.2 | 4.1 | +50% |
| Price / sales | 1.2 | 3.4 | −64% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.3 out of 10 (median for Healthcare: 4.7).
Average analyst target: 59.00 USD, +36.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 5.7 (sector 5.5), Growth 7.9 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 25.3
- Forward P/E
- 15.8
- EV / EBITDA
- 21.1
- Price / book
- 6.2
- Price / sales
- 1.2
- PEG
- 1.08
- Market cap
- 6.8B USD
- Enterprise value
- 10.1B USD
Profitability
- ROE
- 27.9%
- ROA
- 4.6%
- ROIC (approx.)
- 9.4%
- Gross margin
- 17.3%
- Operating margin
- 7.7%
- Net margin
- 4.8%
- Free cash flow
- 378.3M USD
- FCF yield
- 5.5%
- Cash conversion
- 79%
Solvency
- Total debt
- 3.4B USD
- Net debt
- 3.2B USD
- Cash
- 164.5M USD
- EBITDA
- 478.3M USD
- Net debt / EBITDA
- 6.77
- Debt / equity
- 305.26
- Current ratio
- 0.91
- Quick ratio
- 0.84
Growth
- Revenue growth
- +9.1%
- Earnings growth
- +51.6%
- EPS (TTM)
- 1.71 USD
- EPS (forward)
- 2.73 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- −0.08
- Analyst consensus
- Strong buy (6)
- Target price
- 59.00 USD
- 52-week range
- 10.31 – 49.49
Recent news
All PACS news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about PACS Group
Is PACS Group stock cheap or expensive?
On P/E and EV / EBITDA, it trades 20% above the Healthcare median on average. Valuation score: 5.3 out of 10 (median for Healthcare: 4.7). Average analyst target: 59.00 USD, +36.6% versus the price. This is not investment advice.
What score does PACS Group get on MeridIAn Screener?
It scores 5.8 out of 10, rank 1,186 of 2,130 (better than 43% of the companies analysed). Its strongest category is Momentum (9.8) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is PACS Group's P/E ratio?
Its P/E is 25.3: the share price equals 25.3 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 15.8.
How much is PACS Group worth on the stock market?
Its market capitalisation is 6.8B USD and its enterprise value, debt included, is 10.1B USD.
How much debt does PACS Group have?
Its net debt (debt minus cash) is 3.2B USD. That is 6.77 times its EBITDA; the Healthcare median is 1.53.
Does PACS Group pay a dividend?
It pays no dividend, or almost none.
How has PACS Group stock performed over the last year?
It has risen 239.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 10.31 and 49.49 USD. Past performance does not guarantee future results.
What do analysts think of PACS Group?
6 analysts cover it; their average recommendation is “Strong buy” and their average target is 59.00 USD (+36.6% versus the price). It is an estimate, not market data.